Copyright
©The Author(s) 2017.
World J Gastroenterol. Jan 21, 2017; 23(3): 505-515
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.505
Published online Jan 21, 2017. doi: 10.3748/wjg.v23.i3.505
Table 1 Baseline clinical characteristics of the enrolled patients
| Characteristics | Patients (n = 1868) |
| Mean age (range), yr | 65 (28-93) |
| Gender | |
| Male | 1072 (57.4) |
| Female | 796 (42.6) |
| Location | |
| Colon | 892 (47.8) |
| Rectum | 957 (51.2) |
| Unknown | 19 (1.0) |
| Histology | |
| Well differentiated | 484 (25.9) |
| Moderate differentiated | 1066 (57.1) |
| Poorly differentiated | 139 (7.4) |
| Unknown | 179 (9.6) |
| Tumor stage | |
| I | 281 (15.0) |
| II | 551 (29.5) |
| III | 667 (35.7) |
| IV | 369 (19.8) |
| Chemotherapy | |
| No | 294 (15.8) |
| Yes | 1574 (84.2) |
Table 2 Clinicopathological findings according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
| Variable | NLR < 3.0 | NLR ≥ 3.0 | P value | PLR < 160 | PLR ≥ 160 | P value |
| (n = 1086) | (n = 782) | (n = 973) | (n = 894) | |||
| T stage | < 0.001 | < 0.001 | ||||
| T1 | 112 | 39 | 112 | 39 | ||
| T2 | 171 | 91 | 159 | 102 | ||
| T3 | 668 | 498 | 579 | 587 | ||
| T4 | 48 | 59 | 41 | 66 | ||
| Unknown | 87 | 95 | 82 | 100 | ||
| N stage | 0.854 | 0.443 | ||||
| N0 | 589 | 434 | 543 | 480 | ||
| N1 | 289 | 201 | 257 | 232 | ||
| N2 | 196 | 138 | 164 | 170 | ||
| Unknown | 12 | 9 | 9 | 12 | ||
| Lymphatic invasion | 0.421 | 0.446 | ||||
| Yes | 349 | 253 | 311 | 291 | ||
| No | 587 | 391 | 524 | 453 | ||
| Unknown | 150 | 138 | 138 | 150 | ||
| Vascular invasion | 0.243 | 0.011 | ||||
| Yes | 193 | 149 | 160 | 182 | ||
| No | 742 | 496 | 675 | 562 | ||
| Unknown | 151 | 137 | 138 | 150 | ||
| Peri-neural invasion | 0.045 | |||||
| Yes | 168 | 142 | 141 | 169 | 0.004 | |
| No | 767 | 502 | 693 | 575 | ||
| Unknown | 151 | 138 | 139 | 150 |
Table 3 Overall survival and disease free survival according to neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio
| NLR | PLR | |||
| Low (< 3.0) | High (≥ 3.0) | Low (< 160) | High (≥ 160) | |
| Overall survival | ||||
| Stage I | ||||
| 3-yr OS rate | 97.0% | 98.2% | 99.3% | 94.7% |
| 5-yr OS rate | 92.6% | 91.9% | 94.8% | 87.3% |
| Stage II | ||||
| 3-yr OS rate | 91.2% | 89.2% | 90.6% | 90.1% |
| 5-yr OS rate | 86.1% | 84.0% | 84.3% | 86.2% |
| Stage III | ||||
| 3-yr OS rate | 79.6% | 73.4% | 82.1% | 71.4% |
| 5-yr OS rate | 69.3% | 60.9% | 69.6% | 61.9% |
| Stage IV | ||||
| 3-yr OS rate | 39.8% | 21.2% | 33.9% | 27.4% |
| 5-yr OS rate | 34.3% | 18.1% | 28.6% | 23.8% |
| Disease free survival | ||||
| Stage I | ||||
| 3-yr DFS rate | 98.3% | 97.4% | 98.7% | 96.6% |
| 5-yr DFS rate | 96.1% | 95.6% | 97.2% | 93.3% |
| Stage II | ||||
| 3-yr DFS rate | 88.5% | 89.3% | 87.8% | 89.9% |
| 5-yr DFS rate | 84.7% | 86.5% | 83.5% | 87.5% |
| Stage III | ||||
| 3-yr DFS rate | 79.2% | 78.1% | 79.8% | 77.2% |
| 5-yr DFS rate | 75.2% | 68.6% | 74.5% | 70.5% |
| Stage IV | ||||
| 3-yr DFS rate | 42.2% | 30.3% | 38.5% | 34.5% |
| 5-yr DFS rate | 37.5% | 26.8% | 34.3% | 30.4% |
Table 4 Prognostic factors by multivariate Cox regression analysis (Stage I and II)
| Predictor | OS | DFS | ||||
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Age | ||||||
| < 60 yr | 1.00 | 1.00 | ||||
| ≥ 60 yr | 1.72 | 1.08-2.76 | 0.023 | 1.44 | 0.91-2.28 | 0.123 |
| Histology | ||||||
| Well/moderate differentiated | 1.00 | 1.00 | ||||
| Poorly differentiated | 1.57 | 0.72-3.47 | 0.260 | 2.46 | 1.25-4.81 | 0.009 |
| T stage | ||||||
| T1/T2 | 1.00 | 1.00 | ||||
| T3/T4 | 1.66 | 0.95-2.90 | 0.074 | 1.62 | 0.94-2.80 | 0.084 |
| Lymphatic invasion | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 0.77 | 0.46-1.28 | 0.306 | 1.02 | 0.62-1.68 | 0.931 |
| Vascular invasion | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.36 | 1.46-3.84 | < 0.001 | 1.11 | 0.64-1.95 | 0.708 |
| Peri-neural invasion | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 2.64 | 1.59-4.35 | < 0.001 | 3.08 | 1.86-5.09 | < 0.001 |
| NLR | ||||||
| Low NLR (< 3.0) | 1.00 | 1.00 | ||||
| High NLR (≥ 3.0) | 1.16 | 0.76-1.76 | 0.498 | 1.06 | 0.69-1.62 | 0.788 |
| PLR | ||||||
| Low PLR (< 160) | 1.00 | 1.00 | ||||
| High PLR (≥ 160) | 1.07 | 0.71-1.62 | 0.744 | 0.98 | 0.64-1.49 | 0.908 |
Table 5 Prognostic factors by multivariate Cox regression analysis (Stage III and IV)
| Predictor | OS | DFS | ||||
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Age | ||||||
| < 60 yr | 1.00 | 1.00 | ||||
| ≥ 60 yr | 1.46 | 1.13-1.89 | 0.004 | 1.10 | 0.84-1.44 | 0.479 |
| Histology | ||||||
| Well/Moderate differentiated | 1.00 | 1.00 | ||||
| Poorly differentiated | 1.90 | 1.36-2.66 | < 0.001 | 1.46 | 0.98-2.14 | 0.058 |
| T stage | ||||||
| T1/T2 | 1.00 | 1.00 | ||||
| T3/T4 | 2.61 | 1.51-4.51 | 0.001 | 3.13 | 1.69-5.78 | < 0.001 |
| Lymphatic invasion | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.19 | 0.91-1.58 | 0.199 | 1.17 | 0.87-1.57 | 0.298 |
| Vascular invasion | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.52 | 1.15-2.01 | 0.003 | 1.39 | 1.03-1.87 | 0.031 |
| Peri-neural invasion | ||||||
| No | 1.00 | 1.00 | ||||
| Yes | 1.45 | 1.10-1.91 | 0.008 | 1.56 | 1.16-2.08 | 0.003 |
| NLR | ||||||
| Low NLR (< 3.0) | 1.00 | 1.00 | ||||
| High NLR (≥ 3.0) | 1.44 | 1.14-1.83 | 0.003 | 1.43 | 1.11-1.85 | 0.005 |
| PLR | ||||||
| Low PLR (< 160) | 1.00 | 1.00 | ||||
| High PLR (≥ 160) | 1.35 | 1.06-1.73 | 0.017 | 1.32 | 1.02-1.69 | 0.034 |
- Citation: Kim JH, Lee JY, Kim HK, Lee JW, Jung SG, Jung K, Kim SE, Moon W, Park MI, Park SJ. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage III and IV colorectal cancer. World J Gastroenterol 2017; 23(3): 505-515
- URL: https://www.wjgnet.com/1007-9327/full/v23/i3/505.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i3.505
